Scholarlink

Background <p>Vedolizumab is a gut-selective, anti–lymphocyte trafficking biologic therapy for inflammatory bowel disease (IBD). Clinical trials have demonstrated the positive impact of vedolizumab on patient quality of life (QoL); however, real-world evidence of its impact is limited. We evaluated vedolizumab impact on QoL of patients with IBD during the first 52 weeks of treatment in real-world practice in the United Kingdom and Ireland.</p> Methods <p>In this prospective observational study, patients with IBD initiated on vedolizumab completed 4 validated IBD-specific QoL questionnaires at baseline and weeks 14, 26, and 52. The primary endpoint was change in mean Short Inflammatory Bowel Disease Questionnaire (SIBDQ) score. Secondary endpoints included changes in mean scores and sub-scores for other QoL questionnaires.</p> Results <p>Overall, 61 patients were enrolled, including 22 with Crohn’s disease (CD) and 39 with ulcerative colitis (UC). At week 52, the mean change in SIBDQ scores from baseline was statistically significant (+ 12.3 [<i>p</i> = 0.0123] for CD and + 10.8 [<i>p</i> = 0.0037] for UC) and clinically meaningful (considered as a ≥ 10-point change). A significant improvement in mean SIBDQ scores was seen as early as week 14 for both CD and UC cohorts (<i>p</i> = 0.0256 and <i>p</i> = 0.0348, respectively).</p> Conclusions <p>These real-world findings, using multiple validated tools, demonstrate that vedolizumab treatment for IBD is associated with measurable improvements in QoL from baseline.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Health-related quality of life outcomes among vedolizumab-treated patients with inflammatory bowel disease in the UK and Ireland: a 52-week observational study (OCTAVO)

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月1日

查看全文
  • Gareth Parkes,
  • Ayesha Akbar,
  • Ian Beales,
  • Martin Buckley,
  • Tom Creed,
  • Said Din,
  • Nikolas Plevris,
  • Niamh Hogan,
  • Nicola Heggs,
  • Simon Meadowcroft,
  • Mike Wallington,
  • Aileen Fraser

摘要

Background

Vedolizumab is a gut-selective, anti–lymphocyte trafficking biologic therapy for inflammatory bowel disease (IBD). Clinical trials have demonstrated the positive impact of vedolizumab on patient quality of life (QoL); however, real-world evidence of its impact is limited. We evaluated vedolizumab impact on QoL of patients with IBD during the first 52 weeks of treatment in real-world practice in the United Kingdom and Ireland.

Methods

In this prospective observational study, patients with IBD initiated on vedolizumab completed 4 validated IBD-specific QoL questionnaires at baseline and weeks 14, 26, and 52. The primary endpoint was change in mean Short Inflammatory Bowel Disease Questionnaire (SIBDQ) score. Secondary endpoints included changes in mean scores and sub-scores for other QoL questionnaires.

Results

Overall, 61 patients were enrolled, including 22 with Crohn’s disease (CD) and 39 with ulcerative colitis (UC). At week 52, the mean change in SIBDQ scores from baseline was statistically significant (+ 12.3 [p = 0.0123] for CD and + 10.8 [p = 0.0037] for UC) and clinically meaningful (considered as a ≥ 10-point change). A significant improvement in mean SIBDQ scores was seen as early as week 14 for both CD and UC cohorts (p = 0.0256 and p = 0.0348, respectively).

Conclusions

These real-world findings, using multiple validated tools, demonstrate that vedolizumab treatment for IBD is associated with measurable improvements in QoL from baseline.